SavedAdd your journal

Journals / Türk Nöroloji Dergisi / 2018 / Cilt: 24 - Sayı: 2

Idarucizumab for Dabigatran Reversal-full Cohort Analysis (RE-VERSE AD Study)

Dabigatranın Etkisinin Tersine Çevrilmesi için İdarucizumab-Tüm Kohort Analizi (RE-VERSE AD Çalışması)

Esme EKİZOĞLU
Pages
199–200
Publication Date
2022-11-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗

Özet

-

🔖

Cite This Article

EKİZOĞLU, E. (2022). Idarucizumab for Dabigatran Reversal-full Cohort Analysis (RE-VERSE AD Study). Türk Nöroloji Dergisi, Cilt: 24 - Sayı: 2, 199–200. https://ajindex.com/articles/636760

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, Nar H, Litzenburger T. Aspecific antidote for dabigatran: functional and structural characterization. Blood 2013;121:3554-3562.
  2. Pollack CV Jr, Reilly PA, Bernstein R, Dubiel R, Eikelboom J, Glund S, Huisman MV, Hylek E, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Sellke F, Stangier J, Steiner T, Wang B, Weitz JI. Design and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost 2015;114:198-205.
  3. Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med 2017;377:431-441.